Nebenwirkungen · Bondronat
Bondronat 6 mg concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 31
HOS-085678 · Präparat HOS-083171
Summary of the safety profile The most serious reported adverse reactions are anaphylactic reaction/shock, atypical fractures of the femur, osteonecrosis for the jaw and ocular inflammation (see paragraph “description of selected adverse reactions”and section 4.4). Treatment of tumour induced hypercalcaemia is most frequently associated with a rise in body temperature. Less frequently, a decrease in serum calcium below normal range (hypocalcaemia) is reported. In most cases no specific treatment was required and the symptoms subsided after a couple of hours/days. In the prevention of skeletal events in patients with breast cancer and bone metastases, treatment is most frequently associated with asthenia followed by rise in body temperature and headache.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-04-08T17:34:00Z · SHA-256 05636f81465a8a67f982eee4655be333acd7e9f5a20c04764f8127645519a0a1 · Passage 8c0906ec98467096e8d0bd9eca45c0e6145d79bd7a47e2d60fb41b540cdb96dd · Zeichen 0–763 im Abschnitt